{"id":"ticagrelor-standard-tablets","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bradycardia"},{"rate":"13-14","effect":"Dyspnea"},{"rate":"4-6","effect":"Bleeding (major and minor)"},{"rate":"2-3","effect":"Ventricular pauses"},{"rate":"0.5-1","effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelet surfaces, blocking platelet activation and aggregation. This antiplatelet effect reduces the formation of pathological blood clots in coronary arteries and other vascular beds. Unlike clopidogrel, ticagrelor's reversible binding allows faster platelet function recovery upon drug discontinuation.","oneSentence":"Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:38.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)"},{"name":"Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction"}]},"trialDetails":[{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT04005729","phase":"PHASE4","title":"Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2019-07-01","conditions":"Out-Of-Hospital Cardiac Arrest, Acute Coronary Syndrome","enrollment":30},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT03822377","phase":"PHASE3","title":"Ticagrelor Administered as Standard Tablet or Orodispersible Formulation","status":"COMPLETED","sponsor":"Azienda Ospedaliero Universitaria di Sassari","startDate":"2019-06-27","conditions":"ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI","enrollment":130},{"nctId":"NCT02617290","phase":"PHASE3","title":"Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-09","conditions":"Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction","enrollment":1900},{"nctId":"NCT02422888","phase":"PHASE4","title":"Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":110},{"nctId":"NCT02046486","phase":"PHASE4","title":"OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)","status":"COMPLETED","sponsor":"University of Patras","startDate":"2014-01","conditions":"ST Elevation Myocardial Infarction","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ticagrelor standard tablets","genericName":"Ticagrelor standard tablets","companyName":"Azienda Ospedaliero Universitaria di Sassari","companyId":"azienda-ospedaliero-universitaria-di-sassari","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}